tiprankstipranks
Abbisko Cayman Limited Reports Significant Revenue Growth and Profit Turnaround
Company Announcements

Abbisko Cayman Limited Reports Significant Revenue Growth and Profit Turnaround

Story Highlights

Invest with Confidence:

Abbisko Cayman Limited ( (HK:2256) ) has shared an update.

Abbisko Cayman Limited announced a positive profit alert, revealing a significant increase in total revenue to approximately RMB504 million for the year ended December 31, 2024, and a profit of no less than RMB10 million, compared to a loss the previous year. This turnaround is largely attributed to the out-licensing agreement for pimicotinib (ABSK021) and a substantial upfront payment from MERCK HEALTHCARE KGAA, marking a pivotal shift in the company’s financial performance.

More about Abbisko Cayman Limited

Abbisko Cayman Limited operates in the pharmaceutical industry, focusing on innovative drug development. The company engages in out-licensing agreements and has been actively expanding its market presence through strategic collaborations.

YTD Price Performance: -1.96%

Average Trading Volume: 3,474,332

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$3B

Find detailed analytics on 2256 stock on TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App